Markets ADXN

Addex Therapeutics Presents Positive Results From GABAB PAM Cough Program

July 15, 2024 — 01:26 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Addex Therapeutics (ADXN) announced that it will present positive results from its novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) chronic cough program at the Thirteenth London International Cough Symposium on July 19.

In guinea pig models of chronic cough, the candidate GABAB positive allosteric modulator (PAM) significantly and dose-dependently reduced cough frequency induced by citric acid (minimal efficacious dose 1 mg/kg), increased cough latency, and demonstrated no signs of tolerance following sub-chronic treatment.

Compared to the GABAB agonist baclofen, the selective GABAB PAM exhibited a wider safety margin by maintaining a separation between its minimal efficacious dose and the dose associated with side effects. Baclofen has antitussive properties but is limited in clinical use due to its short half-life and central nervous system side effects, such as sedation.

For More Such Health News, visit rttnews.com.

RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source

Tags

Markets
Stocks Mentioned
ADXN

Latest Articles
Data is currently not available